论文部分内容阅读
以碘油（LPD）为载体对原发性肝癌实施导向综合治疗的实验和临床研究的初步结果．125I－LPD经肝动脉灌注后长期高选择性滞留在肝癌组织，其在大鼠肝癌的有效半衰期可达8．73±3．54天，125I－LPD与ADM和MMC的混合乳剂．对肝癌患者的导向综合治疗（内辐射，选择性化疗及栓塞）明显优于LPD的栓塞化疗．经患者肝动脉留量导管，反复多次治疗，可使肝癌组织的内辐射吸收剂量由单次给药的34±7．58rad，提高到94±12．30rad，患者的1年和2年生存率，分别提高至72％和42％．本组的研究结果初步表明，125I－LPD为主的导向综合治疗，是一种安全，有效的治疗肝癌的新方法．
The initial results of experimental and clinical studies of the introduction of lipiodol (LPD) as a carrier for the implementation of a comprehensive treatment of primary liver cancer. After 125I-LPD was perfused through the hepatic artery, it remained in hepatoma tissue for a long time, and its effective half-life in rat hepatoma was 8.73±3.54 days. 125I-LPD was mixed with ADM and MMC. The comprehensive treatment of liver cancer patients (internal radiation, selective chemotherapy and embolization) was significantly superior to LPD embolization chemotherapy. After hepatic arterial catheterization in patients with repeated treatment, the internal radiation absorption dose of hepatocellular carcinoma can be increased from 34±7.58 rad for a single dose to 94±12.30 rad, and the patients can survive for 1 year and 2 years. The rates were increased to 72% and 42%, respectively. The results of this group of studies preliminarily showed that 125I-LPD-based guided comprehensive therapy is a safe and effective new method for the treatment of liver cancer.